Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 01, 2019 08:30 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics to Host Fourth Quarter & Full Year 2018 Financial Results and Business Update Conference Call

NEW HAVEN, Conn., March 01, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...
February 06, 2019 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics to Present at 2019 BIO CEO & Investor Conference

NEW HAVEN, Conn., Feb. 06, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), today announced that Dr. Vimal Mehta, Chief Executive Officer of BTI, will...
February 04, 2019 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Expands Indication for Lead Neuroscience Asset, BXCL501, to Treat Symptoms Associated with Opioid Drug Withdrawal

Clinical benefit observed in 10 of 10 patients; Human proof-of-concept established Provides further evidence of BXCL501’s mechanism of action Expands clinical advisory board with four additional...
January 03, 2019 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Reports Positive Human Proof-of-Concept Data for Acute Treatment of Agitation in Patients with Alzheimer’s Disease

Primary endpoint (safety and tolerability) met, with clinical benefit observed in 7 of 10 patients Proof-of-Concept established in agitated patients across multiple underlying disorders including...
December 27, 2018 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL501 for Acute Treatment of Agitation

NEW HAVEN, Conn., Dec. 27, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), today announced that the U.S. FDA has granted Fast Track Designation for its...
December 19, 2018 04:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Doses First Subjects in Pharmacokinetic (Bioavailability) and Safety Study of BXCL501 for the Acute Treatment of Agitation

Data read-out expected in 1H 19 Results expected to support dose selection for anticipated registration trials in 2019 NEW HAVEN, Conn., Dec. 19, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics,...
December 12, 2018 04:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Announces FDA Acceptance of IND for Lead Neuroscience Candidate, BXCL501 for the Acute Treatment of Agitation

First-in-human pharmacokinetic (bioavailability) study with sublingual thin-film formulation Patient recruitment initiated and data read-out expected in 1H 19 Results to support dose selection for...
December 03, 2018 06:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference

NEW HAVEN, Conn., Dec. 03, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...
November 14, 2018 04:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Reports Positive Results from Study in Agitated Schizophrenia Patients Supporting BXCL501 Clinical Development

Primary endpoint met, clinical benefit observed in 9 of 10 patients treated with intravenously (IV)-dosed Dexmedetomidine(Dex); no meaningful responses observed in placebo arm IV Dex well tolerated...
November 09, 2018 07:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Reports Third Quarter 2018 Quarterly Results and Provides Business Update

NEW HAVEN, Conn., Nov. 09, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...